HIV PrEP program in general practice
Part of Immune system & allergy, Infections clinical trials.
This study helps make HIV PrEP (a daily pill to prevent HIV) more available through your regular general practitioner, instead of only at specialized clinics. You may qualify if you are at risk for HIV and want to start or restart PrEP.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older
- You have tested negative for HIV within the last 7 days (or have a confirmed negative HIV viral load)
- You are visiting a general practitioner for a first PrEP prescription, a renewal after a break of 4 months or more, or for another reason and think you might need PrEP
- You belong to a group with higher HIV risk (such as men who have sex with men, transgender individuals with male partners, people from high-HIV regions, sex workers, injectable drug users, or partners of these groups) OR have had a high-risk situation like many partners, a partner with HIV, condomless sex, an STI, or sexual assault in the last year
- You have health insurance coverage in France (social security)
- You do not have a kidney problem (creatinine clearance below 60) or allergy to PrEP medications
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial checks how well PrEP pills (TDF/FTC) prevent HIV in people who are at high risk and are HIV-negative. It may help you understand whether PrEP is a good prevention option for your situation.
This trial tests a program where HIV testing counselors help family planning patients learn about and get PrEP, a daily pill that prevents HIV. It aims to make PrEP easier to access in clinics you may already visit.
This study checks whether taking HIV prevention medicine called PrEP can help protect people who are not living with HIV but have recent risk of HIV exposure. You may qualify if you have ongoing risk and are not already taking PrEP.
This study helps connect young people aged 13–24 to PrEP, a daily pill that prevents HIV. It tests whether offering PrEP in clinics or community locations makes it easier for you to get and stay on this prevention medication.
This study is for cis-gender men who are HIV-negative and at risk for HIV. It tests a program to help you start and stay on PrEP (medication to prevent HIV).
This study follows adults who are at high risk of getting HIV while they take HIV prevention pills (PrEP). It aims to learn how well PrEP fits real-life use in people at risk and who may need extra care.
Hear when a new Human Immunodeficiency Virus trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.